Jun Ishigooka   Kazuyuki Nakagome   Tetsuro Ohmori   Nakao Iwata   Ken Inada   Jun-Ichi Iga   Taro Kishi   Kiyoshi Fujita   Yuka Kikuchi   Toshiaki Shichijo   Hideaki Tabuse   Shotatsu Koretsune   Hiroshi Terada   Haruko Terada   Toshifumi Kishimoto   Yuichiro Tsutsumi   Yoshiki Kanda   Kazutaka Ohi   Kanji Sekiyama   
Psychiatry and clinical neurosciences 76(1) 22-31 2021年10月
AIM: Globally, evidence from short-term studies is insufficient for the guidelines to uniformly recommend a particular antipsychotic(s) for the maintenance treatment of schizophrenia. Therefore, long-term comprehensive evaluation of antipsychotics...
Most conventional insomnia medications are gamma-aminobutylic acid receptor agonists. However, physical dependence is a concern and one of the major limiting factors for long-term treatment. The dual orexin receptor antagonists, suvorexant and lem...
Taro Kishi   Hiroshi Nakamura   Nakao Iwata   
Psychopharmacology 2021年9月
RATIONALE: We conducted a meta-analysis of double-blind, randomized placebo-controlled trials of lurasidone (LUR) to examine the difference in the risk ratios (RRs) for adverse events (AEs) between depressive disorders (bipolar depression and majo...
AIM: We conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long-acting injectable second-generation antipsychotic (LAI-SGA) therapy due to adverse events (AEs). METHODS: The study included...
Yuki Matsuda   Ryuichi Yamazaki   Taro Kishi   Nakao Iwata   Masahiro Shigeta   Shinsuke Kito   
Neuropsychobiology 1-9 2021年7月
INTRODUCTION: Repetitive transcranial magnetic stimulation (rTMS) has been employed worldwide for therapy-resistant depression. The Food and Drug Administration has approved a number of therapeutic devices for treating major depressive disorder; h...
RATIONALE: What is the difference between aripiprazole and brexpiprazole? OBJECTIVES: This systematic review, network meta-analysis of randomized trials evaluated the efficacy and safety/tolerability of aripiprazole and brexpiprazole for treating ...
INTRODUCTION: The use of the blonanserin patch (BLO-P) for schizophrenia treatment was approved in Japan in 2019. This systematic review of trials in Japan assessed the efficacy and safety profile of BLO-P compared with other antipsychotics. METHO...